KOCAA
DNLI icon

Knights of Columbus Asset Advisors’s Denali Therapeutics DNLI Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
67,591
+11,262
+20% +$231K 0.09% 230
2026
Q1 		$1.08M Buy
56,329
+7,322
+15% +$146K 0.06% 257
2025
Q4 		$809K Sell
49,007
-1,183
-2% -$20K 0.05% 271
2025
Q3 		$729K Buy
50,190
+11,711
+30% +$168K 0.04% 276
2025
Q2 		$538K Sell
38,479
-1,796
-4% -$25.3K 0.03% 277
2025
Q1 		$548K Buy
40,275
+1,058
+3% +$20.3K 0.04% 260
2024
Q4 		$799K Buy
39,217
+98
+0.3% +$2.51K 0.05% 248
2024
Q3 		$1.14M Sell
39,119
-18,876
-33% -$468K 0.08% 235
2024
Q2 		$1.35M Buy
57,995
+18,554
+47% +$356K 0.09% 241
2024
Q1 		$809K Sell
39,441
-37,911
-49% -$712K 0.06% 251
2023
Q4 		$1.66M Buy
77,352
+39,224
+103% +$777K 0.11% 238
2023
Q3 		$787K Buy
38,128
+1,151
+3% +$29.2K 0.07% 247
2023
Q2 		$1.09M Buy
+36,977
New +$1.04M 0.1% 241

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Knights of Columbus Asset Advisors's DNLI Position: Q2 2026 in Review

Knights of Columbus Asset Advisors increased its Denali Therapeutics (DNLI) stake by 20% in Q2 2026, buying an estimated $231K and bringing the position to 67,591 shares worth $1.74M. The position accounts for 0.09% of the portfolio, ranked #230.

Knights of Columbus Asset Advisors first reported a position in DNLI in Q2 2023 and has held it in 13 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Knights of Columbus Asset Advisors held 67,591 shares of Denali Therapeutics worth $1.74M as of Q2 2026.
  • Knights of Columbus Asset Advisors bought 11,262 Denali Therapeutics shares in Q2 2026, an estimated $231K.
  • Denali Therapeutics made up 0.09% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #230 holding.
  • Knights of Columbus Asset Advisors first reported a position in Denali Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.